Fig. 6

Baseline plasma NTA-tau association with cognitive decline. Associations between baseline plasma NTA-tau levels and longitudinal cognitive measures (A and C: MMSE, B and D: mPACC) in BioFINDER-2 (A and B) and BioFINDER-1 (C and D). We used linear mixed models with cognitive measures as outcome and the interaction of baseline plasma biomarkers and time as predictor with random intercepts and random time-slopes. Age, sex and years of education were used as covariates. Dots and thin lines represent individual timepoints and trajectories, respectively, for each participant. Each participant is coloured based on its baseline plasma NTA-tau levels. Thick lines and shaded areas represent the mean trajectory over time of each group of plasma NTA-tau baseline levels and its 95%CI. Only Aβ+ within the AD continuum (excluding nonAD+) were included in these analyses, as were those expected to progress. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Abbreviations: Aβ, amyloid-β; AD, Alzheimer’s disease; CI, confidence interval; MMSE, Mini-Mental State Examination; mPACC, mPACC, modified preclinical Alzheimer’s cognitive composite; nonAD+ ; non-Alzheimer’s type dementia Aβ-positive